Italy, October 10th, 2024 – For the fourth consecutive year, PQE Group is among the winners in the 7th edition of the Best Managed Companies Award, which recognizes entrepreneurial excellence in Made in Italy. This award is promoted by Deloitte Private in collaboration with ELITE-Euronext Group, Piccola Industria Confindustria, and with the methodological and strategic support of ALTIS Graduate School of Sustainable Management at the Catholic University of the Sacred Heart.
WASHINGTON, Oct. 10, 2024 (GLOBE NEWSWIRE) — To support the global need for innovation in pediatric medical device development, the Alliance for Pediatric Device Innovation (APDI), a consortium funded by the U.S. Food and Drug Administration (FDA) and led by Children’s National Hospital, is partnering with DeCODe, a new European Commission-funded device consortium, to advance medical technologies that benefit children. DeCODe was formed to catalyze innovation and address the unique healthcare needs of children with rare diseases.
WASHINGTON, Oct. 10, 2024 (GLOBE NEWSWIRE) — To support the global need for innovation in pediatric medical device development, the Alliance for Pediatric Device Innovation (APDI), a consortium funded by the U.S. Food and Drug Administration (FDA) and led by Children’s National Hospital, is partnering with DeCODe, a new European Commission-funded device consortium, to advance medical technologies that benefit children. DeCODe was formed to catalyze innovation and address the unique healthcare needs of children with rare diseases.
Olivia Schwern – Associate @ J.P. Morgan | Life Sciences Private Capital
COLUMBIA, Md., (October 10, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $100,000 Pre-Seed Builder Fund investment in PerSoN, a company creating digital health solutions to support complex mental health conditions. Businesses receiving an investment from TEDCO’s Pre-Seed Builder Fund, housed under TEDCO’s Social Impact Funds, receive access to a variety of benefits designed to nurture business growth.
BURLINGTON, Mass., October 09, 2024–(BUSINESS WIRE)–MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has opened its new €290 million biosafety testing facility in Rockville, Maryland, USA. Biosafety testing and analytical development are fundamental components of drug development and commercialization for traditional and novel modalities. Global demand for these services is growing at a double-digit rate1.
Children’s National Hospital in Washington, D.C., was ranked as a top hospital in the nation by the U.S. News & World Report 2024-25 Best Children’s Hospitals annual rankings. This marks the eighth straight year Children’s National has made the Honor Roll list. The Honor Roll is a distinction awarded to only 10 children’s hospitals nationwide.
This year, U.S. News ended ordinal rankings on its Honor Roll. Instead of assigning a numerical rank from 1 to 10, all hospitals on the Honor Roll will be recognized as having attained the highest standards of care in the nation.
I
[SEONGNAM, S. Korea, October 8, 2024] SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company has signed an agreement to acquire a stake in Fina Biosolutions (FinaBio), a promising R&D biotechnology company based in Rockville, Maryland, United States, by investing USD 3 million. With this acquisition, SK bioscience will become FinaBio’s first and sole strategic investor.
CHARLOTTESVILLE, Va., October 8, 2024 — AMPEL BioSolutions announced a precision medicine blood test that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies. Inflammatory and immune system abnormalities identified in the blood of individuals predisposed to heart disease by AMPEL two years ago were confirmed and extended in the peer-reviewed Cell iScience paper announced today. Examination of genes expressed in single cells isolated from atherosclerotic coronary artery plaques revealed biomarkers that can be measured by AMPEL’s CardioGENE® blood test.
Program aims to reduce drug safety failure rate and improve efficacy prediction before clinical trials start
The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS), today announced a new funding opportunity through its Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program. CATALYST intends to create human physiology-based computer models to accurately predict safety and efficacy profiles for Investigational New Drug (IND) candidates.
